SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Octagam

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed in the US since 2004 (Octagam 5%) and 2014/2015/2021 (Octagam 10% for various indications).
Why 3/10
No hard, dated binary catalyst is scheduled for Octagam in the next ~12 months; the drug is already approved and marketed across all its indications. The impact score is low (3) because Octagam is a mature, commercialized product with no pending regulatory decision and represents a negligible fraction of Pfizer's $62-64B annual revenue.
Actionable Insight NEUTRAL

Octagam is an already-approved, marketed IVIg product with no pending FDA decision or pivotal readout. For Pfizer investors, this drug is immaterial to the stock thesis; watch the broader IVIg market for pricing and supply dynamics, but Octagam alone will not move PFE shares.

Price Chart

Loading chart...

Executive Summary

Octagam (immune globulin intravenous, human) is an IVIg product developed by privately held Octapharma AG and marketed in the US by Pfizer under a license agreement. FDA-approved since 2004 for primary humoral immunodeficiency, with later approvals for chronic ITP (2015) and adult dermatomyositis (2021, with orphan exclusivity through 2028). The drug is a mature, commercialized product with no pending regulatory catalysts. For Pfizer, a $62-64B revenue company, Octagam is a minor product in a crowded IVIg market and is not a material stock driver.

How It Works

Octagam is an intravenous immunoglobulin (IVIg) product made from purified human antibodies (immunoglobulin G) collected from thousands of healthy plasma donors. When infused into a patient, it provides a broad supply of ready-made antibodies that bolster the immune system to fight infections (in immunodeficiency), block harmful immune cells from destroying platelets (in ITP), and reduce inflammation in muscles and skin (in dermatomyositis).

Trial Status

Octagam is fully FDA-approved and commercially available in the US. Octagam 5% was initially approved May 21, 2004 for primary humoral immunodeficiency. Octagam 10% was approved September 2015 for chronic ITP and July 2021 for adult dermatomyositis (with 7-year orphan drug exclusivity). An additional FDA approval letter was issued April 1, 2022 for both concentrations.

The Two-Sided Case

▲ Bull Case4
Octagam is FDA-approved for three distinct indications: primary humoral immunodeficiency (since 2004), chronic ITP (since 2015), and adult dermatomyositis (since 2021, with 7-year orphan drug exclusivity through 2028).
As an IVIg product, Octagam benefits from steady demand driven by patients with chronic immune deficiencies who require regular infusions.
Pfizer's US marketing infrastructure and existing relationships with specialty pharmacies and payers provide a stable commercial channel for the product.
Octagam 10% is the first and only IVIg approved for adult dermatomyositis, a niche orphan indication with limited direct competition.
▼ Bear Case4
Octagam is a very small product within Pfizer's massive $62-64B annual revenue base and is not broken out as a material product in Pfizer's financial reporting.
The IVIg market is highly competitive with at least 11 FDA-approved IVIg products (Gammagard, Privigen, Gamunex-C, Panzyga, etc.), pressuring pricing and market share.
Octapharma, the drug's manufacturer, is a privately held Swiss company; Pfizer only holds US marketing rights under a license agreement, limiting Pfizer's strategic control over the asset.
IVIg products have faced FDA shortage listings due to manufacturing delays, creating supply-chain risk.

Upcoming Catalysts

  • No upcoming binary catalysts identified; Octagam is a mature, approved product with no pending PDUFA dates, label-expansion filings, or pivotal readouts.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 drugs.com2 pfizer.com3 fda.gov4 octapharma.com5 octapharma.com6 en.wikipedia.org7 drugs.com8 stocktitan.net9 pmarketresearch.com10 ameripharmaspecialty.com11 fda.gov12 ndclist.com